NewAmsterdam Research Development from 2010 to 2026

NAMSW Stock   23.95  0.85  3.68%   
NewAmsterdam Pharma Research Development yearly trend continues to be fairly stable with very little volatility. Research Development will likely drop to about 94.9 M in 2026. During the period from 2010 to 2026, NewAmsterdam Pharma Research Development regression line of quarterly data had mean square error of 1659 T and geometric mean of  14,286,023. View All Fundamentals
 
Research Development  
First Reported
2020-03-31
Previous Quarter
27.5 M
Current Value
31 M
Quarterly Volatility
16.1 M
 
Covid
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 20.4 M, Interest Income of 20.4 M or Depreciation And Amortization of 136.4 K, as well as many indicators such as Price To Sales Ratio of 32.1, Dividend Yield of 0.0 or PTB Ratio of 1.82. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
  
Build AI portfolio with NewAmsterdam Stock
Check out the analysis of NewAmsterdam Pharma Correlation against competitors.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

Latest NewAmsterdam Pharma's Research Development Growth Pattern

Below is the plot of the Research Development of NewAmsterdam Pharma over the last few years. It is NewAmsterdam Pharma's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

NewAmsterdam Research Development Regression Statistics

Arithmetic Mean44,114,562
Geometric Mean14,286,023
Coefficient Of Variation142.49
Mean Deviation52,475,971
Median4,941,363
Standard Deviation62,857,348
Sample Variance3951T
Range169.2M
R-Value0.78
Mean Square Error1659T
R-Squared0.61
Significance0.0002
Slope9,692,717
Total Sum of Squares63216.7T

NewAmsterdam Research Development History

202694.9 M
2025174.1 M
2024151.4 M
2023159.4 M
202286.7 M
202129 M

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma investors use historical fundamental indicators, such as NewAmsterdam Pharma's Research Development, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NewAmsterdam Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Research Development174.1 M94.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.